chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took the third dose of Vivotif three days after the first dose and the fourth dose of Vivotif six days after the first dose; Case reference number US-BN-2024-000051 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0071) on 11-Jan-2024 and concerns a 37-year-old female patient.  The patient's medical history and concomitant medication details were not provided.  On 05-Jan-2024, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally for typhoid fever prophylaxis.  On 07-Jan-2024, two days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, orally.  On 08-Jan-2024, three days after the first dose of Vivotif, the patient took the third dose of Vivotif (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered').  On 11-Jan-2024, six days after the first dose of Vivotif, the patient took the fourth dose of Vivotif (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered').  At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A 37-year-old female patient took the third dose of Vivotif on the day 3 after the first dose, which is considered as inappropriate schedule of vaccine administered. Reportedly, on the day 6 after the first dose, the patient took the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 37-year-old female patient took the third dose of Vivotif on the day 3 after the first dose, which is considered as inappropriate schedule of vaccine administered. Reportedly, on the day 6 after the first dose, the patient took the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took Vivotif capsules two days in a row instead of every other day.; Case reference number US-BN-2024-000052 is a spontaneous case report initially received from a pharmacist via Med Communication (reference number: USBAV24-0075) on 11-Jan-2024 and concerns a male patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.   On unspecified date, the patient took a dose of Vivotif (batch number: unknown) at an unknown dose, orally for typhoid prophylaxis.  On an unspecified date, reported as two days in a row instead of every other day, the patient took another dose of Vivotif (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered').    At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A male patient of unspecified age took a dose of Vivotif for typhoid prophylaxis. Reportedly, on an unspecified date, reported as two days in a row instead of every other day, the patient took another dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took a dose of Vivotif for typhoid prophylaxis. Reportedly, on an unspecified date, reported as two days in a row instead of every other day, the patient took another dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: F
Vaccine: TYP
Symptoms: Product storage error
Clinical narrative: The patient took one capsule of Vivotif and the reporter was not sure if the product already suffered temperature excursion, which was two to ten days stood at max temperature of 20 degrees of Celsius; The patient took one capsule of Vivotif and the reporter was not sure if the product already suffered temperature excursion, which was two to ten days stood at max temperature of 20 degrees of Celsius; Case reference number US-BN-2024-000079 is a spontaneous case report initially received from a pharmacist via Med Communication (reference number: USBAV24-0114) on 18-Jan-2024 and concerns female patient of unspecified age.  The patient's relevant medical history and concomitant medications were not provided.  On unspecified date, the patient took a dose of Vivotif (batch number: unknown), at a dose reported as one capsule, orally, for unknown indication. As reported, the reporter was not sure if the product already suffered temperature excursion, which was two to ten days stood at max temperature of 20 degrees of Celsius (explicitly coded as 'product storage error' and 'product administration error').  At the time of this report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information provided.  Non-significant case correction was received on 14-Feb-2024 from the reporter, included confirmation that they have no further information regarding this case.; Reporter's Comments: A female patient of unspecified age took a dose of Vivotif for unknown indication. As reported, the reporter was not sure if the product already suffered temperature excursion, which was two to ten days stood at max temperature of 20 degrees of Celsius, which is considered as product storage error and product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took a dose of Vivotif for unknown indication. As reported, the reporter was not sure if the product already suffered temperature excursion, which was two to ten days stood at max temperature of 20 degrees of Celsius, which is considered as product storage error and product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: F
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took the second and the third dose of Vivotif two days in a row; Case reference number US-BN-2024-000084 is a spontaneous case report initially received from nurse via Med Communications (reference number: USBAV24-0120) on 19-Jan-2024 and concerns a female patient.  The patient's medical history and concomitant medication details were not provided.  On 15-Jan-2024, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose or route of administration, for unknown indication.  On 17-Jan-2024, two days after first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose or route of administration.  On 18-Jan-2024, three days after first dose of Vivotif, as reported two days in a row with the second dose, the patient took the third dose of Vivotif (batch number: unknown), at an unknown dose or route of administration, for unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A female patient took the second and third dose of Vivotif, two days in a row for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A female patient took the second and third dose of Vivotif, two days in a row for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Sex: F
Vaccine: TYP
Symptoms: Blister, Rash
Clinical narrative: Blisters on eyelids; The patient developed a rash eight-ten years ago on face after taking Vivotif; Case reference number US-BN-2024-000085 is a spontaneous case report initially received from a healthcare professional via Med Communications (reference number: USBAV24-0121) on 19-Jan-2024 and concerns a female patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.   On an unspecified date, the patient took a dose of Vivotif (batch number: unknown), at an unknown dose, orally, for an unknown indication.  On an unspecified date, an unknown amount of time after the vaccination with the Vivotif vaccine, as reported the patient developed a rash eight-ten years ago, on the face. The patient went to the emergency room, and they concluded that it was possibly related to the oral typhoid vaccine. The reporter added that the patient had blisters on eyelids, and the patient had nothing else implicated at the time like creams.   The reporter asked if the crossover could be done between the oral vaccine and the injectable, if some had a reaction to the oral vaccine, they had the injectable and vice versa. As healthcare professional their preference would not be to repeat the oral vaccine because they did not know for sure if it was the vaccine, gelatin, or something else.   At the time of the initial report, it was unknown if the patient recovered from the events of blisters on eyelids and a rash face.  The reporter assessed the events of blisters on eyelids and rash face as non-serious. The reporter assessed causality assessment as related for the events of blisters and rash face to the Vivotif vaccine.  No further information was provided.; Reporter's Comments: A female patient of unspecified age experienced non-serious events of blister and rash on an unspecified date, an unknown amount of time after the patient took a dose of Vivotif for an unknown indication. Rash is listed and expected for Vivotif according to the CCDS v8 and USPI, whilst blister is unlisted and unexpected. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the events have been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age experienced non-serious events of blister and rash on an unspecified date, an unknown amount of time after the patient took a dose of Vivotif for an unknown indication. Rash is listed and expected for Vivotif according to the CCDS v8 and USPI, whilst blister is unlisted and unexpected. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the events have been considered as related to Vivotif. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Product dose omission issue
Clinical narrative: The patient forgot to take the fourth dose of Vivotif vaccine on day seven.; Case reference number US-BN-2024-000089 is a spontaneous case report initially received from other healthcare professional via Med Communication (reference number: USBAV24-0139) on 22-Jan-2024 and concerns a 19-year-old male patient.   The patient's medical history and concomitant medication details were not provided.  On 15-Jan-2024, the patient took the first dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally, for typhoid fever prophylaxis. As reported the patient had started the seven day series.  On 17-Jan-2024, two days after receiving the first dose of Vivotif, the patient took the second dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally.  On 19-Jan-2024, four days after receiving the first dose of Vivotif, the patient took the third dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally. As reported, the patient forgot to take the fourth dose of Vivotif since the patient was going on different trip and before leaving the country (explicitly coded as 'missed dose').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A 19-year-old male patient took three doses of Vivotif for typhoid fever prophylaxis, and reportedly forgot to take the fourth dose, which is considered as product dose omission issue. No associated adverse events were reported. Product dose omission issue is listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A 19-year-old male patient took three doses of Vivotif for typhoid fever prophylaxis, and reportedly forgot to take the fourth dose, which is considered as product dose omission issue. No associated adverse events were reported. Product dose omission issue is listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to Vivotif, but to a human factor. The case is non-serious.
Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took second dose of Vivotif, five days after the first dose; Case reference number US-BN-2024-00092 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0141) on 22-Jan-2024 and concerns a male patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.  On unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for unknown indication.  On unspecified date, as reported five days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered').   On an unspecified dates, as reported every other day, the patient took the third and the fourth dose of Vivotif (batch number: unknown), at an unknown dose, orally.   At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A male patient of unspecified age took the second dose of Vivotif five days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A male patient of unspecified age took the second dose of Vivotif five days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Sex: F
Vaccine: TYP
Symptoms: Product storage error
Clinical narrative: Patient took three doses of Vivotif vaccine that was exposed to minimum temperature of 65 degrees Fahrenheit and maximum temperature of 72 degrees Fahrenheit for seven days; Patient took three doses of Vivotif vaccine that was exposed to minimum temperature of 65 degrees Fahrenheit and maximum temperature of 72 degrees Fahrenheit for seven days; Case reference number US-BN-2024-000096 is a spontaneous case report initially received from a physician via Med Communication (reference number: USBAV24-0151) on 23-Jan-2024 and concerns a female patient of unspecified age.  The patient's relevant medical history and concomitant medications were not provided.  On unspecified dates, the patient took first, second and third dose of Vivotif (batch number: unknown), at a dose reported as one capsule, orally, for unknown indication.  It was reported that patient took three capsules of Vivotif vaccine from the box that was exposed to minimum temperature of 65 degrees Fahrenheit and maximum temperature of 72 degrees Fahrenheit for seven days (explicitly coded as 'product storage error' and 'product administration error').  At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.  Non-significant case correction performed on 09-Feb-2024 for the information received on 24-Jan-2024 included: additional reference numbers.; Reporter's Comments: A female patient of unspecified age took three capsules of Vivotif vaccine for unknown indication, from the box that was exposed to minimum temperature of 65 degrees Fahrenheit and maximum temperature of 72 degrees Fahrenheit for seven days, which is considered as product storage error and product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took three capsules of Vivotif vaccine for unknown indication, from the box that was exposed to minimum temperature of 65 degrees Fahrenheit and maximum temperature of 72 degrees Fahrenheit for seven days, which is considered as product storage error and product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took Vivotif day one dose and day three dose two days in a row, as reported the first dose was yesterday and the second dose as today; Case reference number US-BN-2024-000100 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0156) on 24-Jan-2024 and concerns a *68-year-old* male patient.  *The patient had no relevant medical history.*  The patient's concomitant medication details were not provided.  On 23-Jan-2024, reported as yesterday, the patient took the first dose of Vivotif *(batch number: 3003852; expiration date: 31-Mar-2024) at a dose of one capsule,* orally, *for indication reported as travel.*  On 24-Jan-2024, one day after the first dose of Vivotif, the patient took the second dose of Vivotif * (batch number: 3003852; expiration date: 31-Mar-2024) at a dose of one capsule,* orally. As reported, the patient took Vivotif day one dose and day three dose two days in a row (explicitly coded as 'inappropriate schedule of vaccine administered').  *As reported, the patient did not experience any adverse event due to Vivotif.*  Additional information received from Bavarian Nordic on 24-Jan-2024 included local BN case ID.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from nurse on 28-Feb-2024: New information included patient demographic details, confirmation of no relevant medical history, Vivotif administration details for first and second dose and confirmation that the patient did not experience any adverse event due to Vivotif.; Reporter's Comments: A male patient of unspecified age took the second dose of Vivotif one day after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of vaccine administered is listed per company convention. The patient had no medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A male patient of unspecified age took the second dose of Vivotif one day after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of vaccine administered is listed per company convention. The patient had no medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Vaccine: TYP
Symptoms: Product administration error
Clinical narrative: Patient took the first dose of Vivotif with a full breakfast; Case reference number US-BN-2024-000158 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0283) on 07-Feb-2024 and concerns a patient of unknown demographics.   The patient's medical history and concomitant medication details were not provided.   On 06-Feb-2024, but reported as health care professional not certain, the patient took the first dose of Vivotif (batch number: not reported) orally, at an unknown dose, for typhoid immunization. As reported, the patient took the first dose of Vivotif with a full breakfast, not on an empty stomach (explicitly coded as 'Product administration error').    At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.   No further information provided.; Reporter's Comments: A patient of unknown demographics took the first dose of Vivotif for typhoid immunization with a full breakfast, not on an empty stomach, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics took the first dose of Vivotif for typhoid immunization with a full breakfast, not on an empty stomach, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Vaccine: TYP
Symptoms: Product administration error
Clinical narrative: The patient administrated a dose of Vivotif vaccine with food instead of one-hour prior meal; Case reference number US-BN-2024-000160 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0284) on 07-Feb-2024 and concerns a patient of unknown demographics.  The patient's medical history and concomitant medications were not provided.  On unspecified date, the patient took a dose of Vivotif vaccine (batch number: unknown), at an unknown dose and route of administration, for unknown indication. As reported, the patient administrated a dose of Vivotif vaccine with food instead of one-hour prior meal (explicitly coded as 'product administration error').  At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information provided.; Reporter's Comments: A patient of unknown demographics administrated a dose of Vivotif vaccine for unknown indication with food instead of one-hour prior meal, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics administrated a dose of Vivotif vaccine for unknown indication with food instead of one-hour prior meal, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Incomplete course of vaccination
Clinical narrative: The patient forgot to take final dose of Vivotif and could not take additionally because of traveling out of country; Case reference number US-BN-2024-000162 is a spontaneous case report initially received from other health care professional via Med Communications (reference number: USBAV24-0278) on 07-Feb-2024 and concerns 56-years-old male patient.  The patient's medical history and concomitant medications were not provided.  On unspecified dates, the patient received the first, the second and third dose of Vivotif (batch number: unknown) at an unknown dose and route of administration, for immunization against disease caused by Salmonella typhi.   As reported, the patient forgot to take final dose of Vivotif and was travelling out of country and did not have pills. The patient would not be able to return home until 24th February and then will immediately depart for another country on the 27th (explicitly coded as 'incomplete course of vaccination').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.   No further information was provided.; Reporter's Comments: A 56-year-old male patient forgot to take the final dose of Vivotif for immunization against disease caused by Salmonella typhi after the patient received the first, the second and third dose of Vivotif, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Incomplete course of vaccination has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 56-year-old male patient forgot to take the final dose of Vivotif for immunization against disease caused by Salmonella typhi after the patient received the first, the second and third dose of Vivotif, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Incomplete course of vaccination has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took one capsule of Vivotif vaccine once daily for four days instead of every other day; Case reference number US-BN-2024-000174, initially received from Med Communications on 09-Feb-2024 (reference number USBAV24-0291), is a spontaneous case received from a pharmacist and concerns a patient of unknown demographics.  The patient's medical history and concomitant medications were not provided.  On unspecified dates, the patient received the first, second, third and fourth dose of Vivotif vaccine (batch number: unknown), at an unknown dose, administered orally for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses (explicitly coded as 'inappropriate schedule of vaccine administered').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A patient of unknown demographics received the first, second, third and the fourth dose of Vivotif vaccine for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics received the first, second, third and the fourth dose of Vivotif vaccine for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took Vivotif every day, instead of every other day; Case reference number US-BN-2024-000198 is a spontaneous case report initially received from a healthcare professional via Med Communications (reference number: USBAV24-0348) on 20-Feb-2024 and concerns a male patient of unknown age.   The patient's medical history and concomitant medication details were not provided.   On an unspecified date, the patient took a dose of Vivotif (batch number: not provided) at an unknown dose, orally, for an unknown indication. As reported, instead of every other day, the patient took Vivotif every day (explicitly coded as 'inappropriate schedule of vaccine administered').    At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccination.   No further information was provided.; Reporter's Comments: A male patient of unknown age took a dose of Vivotif for an unknown indication. As reported, instead of every other day, the patient took Vivotif every day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccination. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age took a dose of Vivotif for an unknown indication. As reported, instead of every other day, the patient took Vivotif every day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccination. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Product administration error
Clinical narrative: Patient ate 15 minutes after taking the first dose of Vivoitf; Case reference number US-BN-2024-000199 is a spontaneous case report initially received from a pharmacist via Med Communication (reference number: USBAV24-0346) on 20-Feb-2024 and concerns a 64-year-old male patient.  The patient's medical history and concomitant medication details were not provided.  On 18-Feb-2024, the patient took a first dose of Vivotif (batch number: unknown) at an unknown dose via oral route, for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose (explicitly coded as 'product administration error').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A 64-year-old male patient took the first dose of Vivotif for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 64-year-old male patient took the first dose of Vivotif for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient took Vivotif once a day, instead of every other day; Case reference number US-BN-2024-000221 is a spontaneous case report initially received from a health care professional via Med Communications (reference number: USBAV24-0378) on 23-Feb-2024 and concerns a patient of unspecified age and gender.  The patient's relevant medical history and concomitant medications were not provided.  On unspecified dates, the patient took doses of Vivotif (batch number: unknown), at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day (explicitly coded as 'inappropriate schedule of vaccine administered').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A patient of unspecified age and gender took doses of Vivotif, at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender took doses of Vivotif, at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took a partial dosage of Vivotif; took one or two pills of Vivotif which were prescribed three weeks ago; Case reference number US-BN-2024-000606 is a spontaneous case report initially received from a nurse via Med Communications (reference number: USBAV24-0448) on 05-Mar-2024 and concerns a 16-year-old male patient.  The patient's medical history and concomitant medication details were not provided.  On an unknown date, the patient took a dose of Vivotif (batch number: unknown), orally, at an unknown dose, for typhoid prophylaxis. As reported, the patient was seen in the clinic three weeks ago (on the 14th), when they were prescribed with Vivotif and the patient took one or two pills (explicitly coded as 'Inappropriate schedule of vaccine administered').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif.  Additional information received from the reporter via Med Communications on 06-Mar-2024: included confirmation of patient's gender and that patient took one or two pills.; Reporter's Comments: A 16-year-old male patient took a dose of Vivotif orally, at an unknown dose, for typhoid prophylaxis. Reportedly, the patient was seen in the clinic three weeks ago, when they were prescribed with Vivotif and the patient took one or two pills which is currently considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 16-year-old male patient took a dose of Vivotif orally, at an unknown dose, for typhoid prophylaxis. Reportedly, the patient was seen in the clinic three weeks ago, when they were prescribed with Vivotif and the patient took one or two pills which is currently considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Vaccine: TYP
Symptoms: Product storage error
Clinical narrative: Vivotif vaccine was stored at 72 Fahrenheit degrees for one week; The patients did the entire course of vaccination after temperature excursion; Vivotif vaccine was stored at 72 Fahrenheit degrees for one week; The patients did the entire course of vaccination after temperature excursion; Case reference number US-BN-2024-000617 is a spontaneous case received from a pharmacist initially received from Med Communications (reference number: USBAV24-0485) on 11-Mar-2024 and concerns two child patients.  The patients' medical history and concomitant medications were not provided.  On an unspecified date, the Vivotif vaccine was exposed to the first temperature excursion reaching a temperature of 72 Fahrenheit degrees for one week (explicitly coded as 'product storage error'). As reported, mother of patients did not put vaccine in refrigerator.   On an unspecified date, an unknown amount of time after the first temperature excursion, patients were vaccinated with Vivotif vaccine (batch number: unknown), at an unknown dose and route of administration for an unknown indication (explicitly coded as 'product administration error'). As reported, patients did the entire course of vaccination.   At the time of the initial report, it was unknown if any of the patients experienced any adverse event due to Vivotif vaccine.  Additional information received on 11-Mar-2024 from a pharmacist via Med Communications: included confirmation about initials and date of birth for second patient and additional reference number (USBAV24-0484).; Reporter's Comments: Two child patients were vaccinated with Vivotif vaccine for an unknown indication, which was exposed to the first temperature excursion reaching a temperature of 72 Fahrenheit degrees for one week, which is considered as product storage error and product administration error. It was unknown if any of the patients experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patients' medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: Two child patients were vaccinated with Vivotif vaccine for an unknown indication, which was exposed to the first temperature excursion reaching a temperature of 72 Fahrenheit degrees for one week, which is considered as product storage error and product administration error. It was unknown if any of the patients experienced any adverse event due to Vivotif vaccine. Product storage error and product administration error are considered as listed per company convention. The patients' medical history and concomitant medications were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Sex: F
Vaccine: TYP
Symptoms: Product dose omission issue
Clinical narrative: The patient only took three out of four doses of Vivotif before the medication was lost; Case reference number US-BN-2024-000644 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0532) on 18-Mar-2024 and concerns a female patient of unknown age.  The patient's medical history and concomitant medication details were not provided.  On unspecified dates, the patient took the first, second, and third dose of Vivotif (batch number: unknown), at an unknown dose or route of administration, for unknown indication. As reported, the patient only took three out of four doses before the medication was lost (explicitly coded as 'missed dose'). The patient wanted to know if the vaccination needed to be restarted.  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif.  No further information was provided.; Reporter's Comments: A female patient of unknown age took the first, second, and third dose of Vivotif for unknown indication. As reported, the patient only took three out of four doses before the medication was lost, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age took the first, second, and third dose of Vivotif for unknown indication. As reported, the patient only took three out of four doses before the medication was lost, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.